Microneedle Array Doxorubicin (MNA-D)

Phase 2Small molecule

Microneedle Array Doxorubicin (MNA-D) is one of 6 small molecule programs targeting Squamous Cell Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Squamous Cell CancerRecruiting

Squamous Cell CancerPhase 2

Recruiting

Competition

Competitive Landscape

5 competitors in Squamous Cell Cancer

#DrugCompanyPhaseTrials

Erbitux

IImclone

Phase 2

3 2

Bavencio

EMD Serono

Phase 2

1 3

Pucotenlimab

SSun Yat-sen University

Phase 2

1 4

MRG003

SShanghai Miracogen Inc.

Phase 2

1 5

Microneedle Array Doxorubicin (MNA-D)

FFalo, Louis, MD

Phase 2

1 6

Tozuleristide

BBlaze Bioscience Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Squamous Cell Cancer

NCT05377905

Clinical

Trials by Indication[1]

Squamous Cell Cancer1 trial

Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)

Recruiting·FFalo, Louis, MD·Phase 1/2·NCT05377905·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Microneedle Array Doxorubicin (MNA-D). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Microneedle Array Doxorubicin (MNA-D) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Microneedle Array Doxorubicin (MNA-D). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Falo, Louis, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFalo, Louis, MD

Microneedle Array Doxorubicin (MNA-D)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Squamous Cell Cancer1 trial

References

Drug Info

Quick Facts

Related News